2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…2018 American Transplant Congress
Brincidofovir Was Used to Successfully Treat Adenovirus Infections in Solid Organ Transplant Recipients and Other Immunocompromised Patients
Background: Adenovirus (AdV) infections cause significant morbidity and mortality in immunocompromised patients. Brincidofovir (BCV) is an investigational antiviral drug with high in vitro potency against…2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…2018 American Transplant Congress
Early Adjunctive Treatment with Human Cytomegaly Virus (CMV) Immunoglobulin Increased CMV-Free Survival after Heart Transplantation
Purpose: There is still an ongoing discussion whether a prophylactic or a preemptive therapy against cytomegalovirus (CMV) is superior to reduce the incidence of CMV…2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…2018 American Transplant Congress
Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients and Role of Prophylaxis
Objectives: Cytomegalovirus (CMV) is an opportunistic infection that can lead to significant complications post-transplant. Purpose of this study was to evaluate the use of valganciclovir…2018 American Transplant Congress
Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients
1University of British Columbia, Vancouver, Canada; 2University of Manitoba, Winnipeg, Canada.
Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is…2018 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…2018 American Transplant Congress
Building a Third-Party VST Bank from Scratch- The Cincinnati Experience
BackgroundViral infections remain a challenge to treat and significantly contribute to morbidity and mortality. Virus specific T cells (VSTs) have shown clinical efficacy, with minimal…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 14
- Next Page »